Blood · 2013
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Bin, Li Min, McDonald Tinisha, Holyoake Tessa L, Moon Randall T, Campana Dario, Shultz Leonard, Bhatia Ravi
Аннотация
Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. TKI treatment effectively inhibits BCR-ABL kinase activity in CML LSCs, suggesting that additional kinase-independent mechanisms contribute to LSC preservation. We investigated whether signals from the bone marrow (BM) microenvironment protect CML LSCs from TKI treatment. Coculture with human BM mesenchymal stromal cells (MSCs) significantly inhibited apoptosis and preserved CML stem/progenitor cells following TKI exposure, maintaining colony-forming ability and engraftment potential in immunodeficient mice. We found that the N-cadherin receptor plays an important role in MSC-mediated protection of CML progenitors from TKI. N-cadherin-mediated adhesion to MSCs was associated with increased cytoplasmic N-cadherin-β-catenin complex formation as well as enhanced β-catenin nuclear translocation and transcriptional activity. Increased exogenous Wnt-mediated β-catenin signaling played an important role in MSC-mediated protection of CML progenitors from TKI treatment. Our results reveal a close interplay between N-cadherin and the Wnt-β-catenin pathway in protecting CML LSCs during TKI treatment. Importantly, these results reveal novel mechanisms of resistance of CML LSCs to TKI treatment and suggest new targets for treatment designed to eradicate residual LSCs in CML patients.
Предметные рубрики MeSH
AnimalsApoptosisBiomarkers, TumorBlotting, WesternBone MarrowCadherinsCell CycleCell ProliferationDrug Resistance, NeoplasmFusion Proteins, bcr-ablGene Expression ProfilingHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMesenchymal Stem CellsMiceMice, NudeNeoplastic Stem CellsOligonucleotide Array Sequence AnalysisPhosphorylationProtein Kinase InhibitorsRNA, MessengerReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionTumor Cells, CulturedTumor Microenvironmentbeta Catenin